Gilead Triple Play
Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes drugs for life threatening diseases. Their products are Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
[PostStockWidget stock_valuation="" pricetype="live" manual_date="Dec. 21, 2012, 2:04pm GMT" symbolcodes="'GILD'" symbolprices="103" div_align="right"]
We like GILD’s size, low P/E rate, high growth rate, strong cash position and the positive outlook for the generic drug industry.
We last sold this stock at $122.80 just a few months ago in June 2015 - the stock has fallen off during the recent volatility and is now 20% lower. Purple Chips 12 -18 month target: $USD 125.00
LOW VALUATION IN GILEAD SCIENCES AT $USD 103.55 (GILD-US) FULL POSITION
PURPLE CHIPS TARGET: $125.00 POSITION SIZE: FULL (5.0) P/E: 9.8X DIV: $1.72 (1.7%) MKT CAP: $149B CASH: $1.8B RETURN ON CAPITAL: 125.1% EARNINGS YIELD: 12.1% 5 YR EPS Growth rate*:15.0% P/E/G Ratio: 0.65 EPS: $10.36 2015 EST.: $11.47 2016 EST.: $12.28
*Blended growth rate= 2/3 historical (5yrs), 1/3 forward.
